These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 32584416)

  • 1. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 3. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
    Carnero Contentti E; Correa J
    Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
    [No Abstract]   [Full Text] [Related]  

  • 6. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
    Smetana K; Brábek J
    In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
    Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
    J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
    Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
    Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
    [No Abstract]   [Full Text] [Related]  

  • 10. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
    Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plea for the pathogenic role of immune complexes in severe Covid-19.
    Vuitton DA; Vuitton L; Seillès E; Galanaud P
    Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 16. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
    Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
    Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.